Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QA6Q | ISIN: US68620A2033 | Ticker-Symbol: 4OR1
Tradegate
20.11.24
21:57 Uhr
0,326 Euro
-0,017
-4,96 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ORGANOVO HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ORGANOVO HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3310,34714:54
0,3360,35214:51

Aktuelle News zur ORGANOVO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ORGANOVO Aktie jetzt für 0€ handeln
MiOrganovo reports positive Phase 2 results for liver drug FXR3148
MiOrganovo, Inc.: Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting4
FrOrganovo stock plunges to 52-week low of $0.35 amid market challenges6
13.11.Organovo, Inc.: Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases10
08.11.ORGANOVO HOLDINGS, INC. - 10-Q, Quarterly Report5
06.11.Organovo stock plunges to 52-week low of $0.39 amid market challenges4
25.10.ORGANOVO HOLDINGS, INC. - S-1, General form for registration of securities11
11.10.Organovo-Aktie erreicht 52-Wochen-Tief bei 0,43 US-Dollar15
11.10.Organovo stock hits 52-week low at $0.43 amid market challenges4
19.09.Organovo stock plunges to 52-week low of $0.5 amid market challenges7
19.09.Aktie von Organovo fällt auf 52-Wochen-Tief von 0,5 US-Dollar19
09.08.Organovo grants stock options to executive chairman16
09.08.ORGANOVO HOLDINGS, INC. - 8-K, Current Report8
05.08.ORGANOVO HOLDINGS, INC. - 10-Q, Quarterly Report9
26.07.ORGANOVO HOLDINGS, INC. - 10-K/A, Annual Report8
24.07.ORGANOVO HOLDINGS, INC. - 8-K, Current Report5
16.07.Organovo, Inc.: Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis28
31.05.ORGANOVO HOLDINGS, INC. - 10-K, Annual Report12
15.04.Organovo, Inc.: Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo360SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration...
► Artikel lesen
06.12.23Organovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results736SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1